Drug Profile
Research programme: antibacterials - Hsiri Therapeutics
Alternative Names: HT-06; HT-07; HT-10Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator University of Notre Dame
- Developer Hsiri Therapeutics
- Class Antibacterials
- Mechanism of Action Bacterial growth inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 16 Jun 2016 Preclinical trials in Bacterial infections in USA (unspecified route)
- 16 Jun 2016 Pharmacodynamics data from an in vitro study in bacterial infections released by Hsiri Therapeutics